Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company’s lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company’s other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline. In January 2010, the Company completed the acquisition of Symphony Dynamo, Inc. (SDI) from Symphony Dynamo Holdings LLC. Pursuant to the acquisition SDI became a wholly owned subsidiary of the Company.

Roche s.r.o in the Czech Republic is just a hop, skip, and a jump away from parent company Roche Holding Ltd. in nearby Switzerland. Its operations are focused more on the parent company's diagnostic products than on its traditional pharmaceuticals; Roche s.r.o. has two facilities in Prague for manufacturing and distributing tests for Hepatitis B and C, HIV, cancer, and other diseases. One is devoted exclusively to diabetic products -- diabetes is a growing problem in the Czech Republic. Roche s.r.o. also markets pharmaceuticals made at other Roche facilities, including such popular therapies as cancer drugs Avastin and Herceptin, lymphona drug MabThera, and osteporosis drug Bonviva.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Vermillion, Inc. is involved in the discovery, development and commercialization of diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers (known as translational proteomics) for developing a procedure to measure a property or concentration of an analyte (known as an assay) and commercializing diagnostic tests. Vermillion has focuses in the areas of oncology, hematology, cardiology and women’s health. Vermillion’s focus on translational proteomics enables it to address the market for diagnostic tests that measure multiple protein biomarkers. In January 2010, the Company emerged from protection under Chapter 11 of the United States Bankruptcy Code.

Avalon Pharmaceuticals doesn't mind if genes express themselves -- but they should know that anything they express can and will be used against them if they lead to cancer. The biopharmaceutical firm develops cancer therapeutics based on its AvalonRx platform, which identifies compounds that would be best suited to advance in clinical drug development. Lead product AVN944, an inhibitor of hematologic (leukemia, lymphoma, and myeloma) and solid tumor cancers, is an oral drug now in clinical trials. Avalon also has preclinical programs to develop inhibitors through partnerships with other drug companies. The company was acquired by Clinical Data in 2009.

Metagenics, Inc., doing business as Ethical Nutrients, manufactures and distributes medical foods and nutraceuticals to healthcare practitioners. The company offers FirstLine Therapy programs for the prevention and management of chronic conditions, including diabetes, cardiovascular disease, and arthritis. It distributes its products in North America, South America, Europe, and Asia. The company was founded in 1983 and is headquartered in San Clemente, California with research and development centers in Gig Harbor, Washington; and Ithaca, New York. It has manufacturing facilities in Gig Harbor, Washington. As of September 11, 2009, Metagenics, Inc. operates as a subsidiary of Alticor Inc.

Archemix Corp., a biotechnology company, engages in discovering, developing, and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases in Massachusetts. The company’s aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. It also offers product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was incorporated in 2000 and is based in Cambridge, Massachusetts.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.